Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives

  1. Reck, M.
  2. Popat, S.
  3. Grohé, C.
  4. Corral, J.
  5. Novello, S.
  6. Gottfried, M.
  7. Brueckl, W.
  8. Radonjic, D.
  9. Kaiser, R.
  10. Heymach, J.
Journal:
Lung Cancer

ISSN: 1872-8332,  0169-5002

Year of publication: 2023

Volume: 179

Type: Review

DOI: 10.1016/J.LUNGCAN.2023.03.009 GOOGLE SCHOLAR

Sustainable development goals

Data source: Scopus